Phase 2
N=94
Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum
Molluscum Contagiosum
Bottom Line
View on ClinicalTrials.gov: NCT02665260 ↗Enrolled (actual)
94
Serious AEs
0.0%
Results posted
May 2017
Primary outcome: Primary: Number of Subjects Who Achieve Complete Clearance at 6 Weeks — 10; 7; 2; 3 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Cantharidin (Drug); Placebo (Drug); Gauze occlusion bandage (Device)
- Age
- Pediatric · 2+ yrs
- Sex
- All
- Sponsor
- Montefiore Medical Center
- Primary completion
- Nov 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Subjects Who Achieve Complete Clearance at 6 Weeks |
10; 7; 2; 3; 14; 16 | — |
| SECONDARY Number of Subjects Who Experienced an Adverse Event |
0; 0; 0; 0; 23; 24 | — |
Summary
The purpose of this study is to determine if cantharidin is a safe and effective treatment for molluscum contagiosum in kids
Eligibility Criteria
Inclusion Criteria
- 2-17years
- Healthy
- <50 molluscum contagiosum lesions
Exclusion Criteria
- Immunosuppressed
- Oral corticosteroids
- Sexually active/pregnant
Data sourced from ClinicalTrials.gov (NCT02665260). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.